Recon: FDA approves ImmunityBio bladder cancer treatment; Lawsuit alleges Novartis promoted asthma drug for preterm labor despite brain risk

• In a scientific first, researchers use CRISPR base editing to treat liver disease in fetal monkeys (STAT)
• Trump surrogates hint at how he could reshape U.S. health care policy (STAT)
• CDS Final Guidance Draws More Criticism, This Time From Congress (MedTech Insight)
• ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages (Pink Sheet)
• Senators to DEA: Consider Treaty Obligations In Marijuana Rescheduling (FDA Law Blog)
• US FDA approves ImmunityBio's bladder cancer therapy (Reuters)
• Alzheimer's drug adoption in US slowed by doctors' skepticism (Reuters)

• Second EU MDR Notified Body Designated In France (MedTech Insight)
• WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency (Pink Sheet)
• Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages (Pink Sheet)
• Pfizer vs Moderna battle over COVID vaccine patents begins in UK (Reuters)
• Novartis 'actively' reviewing relationships with Chinese contractors amid US biosecurity crackdown: CFO (Reuters)
• Novartis raises guidance after beating Q1 expectations (Reuters)

• Looking for signs of growth in Biogen’s earnings (STAT)
• Pascal Soriot’s been pushing for US-sized CEO pay for more than a decade. Now he’s finally getting it (Endpoints)
• Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D (Endpoints)
• MarketingRx roundup: Cannes ad festival speakers to include Pfizer, Novo Nordisk; AZ adds TV commercial to NHL collab (Endpoints)
• Novartis’ simplified strategy takes shape as the company seeks former Bristol Myers CEO as chair (Endpoints)
• Novartis accused of promoting asthma drug for preterm labor despite brain risk (Reuters)
• Brise raises $20M; Taro shareholder criticizes Sun Pharma deal (Endpoints)
• Pharma companies tone down ESG mentions, but not ambitions (Endpoints)
• Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director (Pink Sheet)
• Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works (Pink Sheet)
• Opinion: Bashing accelerated approval isn’t supported by the data (STAT)
• Opinion: Use evidence to support early coverage of gene therapy after accelerated approval (STAT)

• Telehealth startups see an opportunity in long-ignored, complex chronic diseases (STAT)
• Accreditation agencies take on telehealth with new virtual care standards (STAT)
• Exclusive: Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup (Endpoints)
• Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217 (MedTech Insight)
• Quest Diagnostics raises 2024 profit and revenue forecast on strong demand (Reuters)

• How a scientific slip-up caused a pregnant woman to get an untested treatment for preterm birth (STAT)
• Gerber, Perrigo sued over 'store-brand' infant formula prices (Reuters)
• US Supreme Court faces fight over emergency abortions after toppling Roe (Reuters)